designer491-3
designer491 / iStockphoto.com
23 January 2018Americas

Celgene reveals plans to acquire Juno for $9bn

Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

The acquisition, worth $9 billion, will help US-based Celgene and Juno discover and develop “transformative medicines for patients with incurable blood cancers”, said Mark Alles, Celgene’s CEO.

Celgene is a New Jersey-based biopharmaceutical company that focuses on delivering innovative drugs for the treatment of cancer, while Washington-based Juno is an experimental drug company that focuses on developing cancer immunotherapy drugs.

“Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in haematology and adds new drivers for growth beyond 2020,” added Alles.

Juno focuses on developing CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics, designed to treat cancer.

Juno’s JCAR017 (lisocabtagene maraleucel; liso-cel), which is a potential CAR T therapeutic, is expected to receive regulatory approval in 2019.

Hans Bishop, president and CEO of Juno, added: “The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives.”

Collaborating with Juno’s Seattle-based team, Celgene plans to expand its centre for immuno-oncology translational medicine.

Earlier this year, Celgene announced that it will acquire Impact Biomedicines for more than $1 billion.

In more mergers and acquisition news, Paris-based Sanofi revealed plans to acquire US-based biotech company Bioverativ for $11.6 billion.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019   Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019   Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019   Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.